ENSC — Ensysce Biosciences Income Statement
0.000.00%
Last trade - 00:00- $4.23m
- $0.70m
- $5.21m
- 38
- 51
- 17
- 27
Annual income statement for Ensysce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3.53 | 2.52 | 2.23 | 5.21 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.37 | 23.4 | 30.7 | 12.9 | 11.9 |
| Operating Profit | -1.37 | -19.9 | -28.2 | -10.7 | -6.73 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 4.56 | -29.1 | -24.2 | -10.6 | -7.99 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4.31 | -29.1 | -24.2 | -10.6 | -7.99 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 4.31 | -29.1 | -24.2 | -10.6 | -7.99 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 4.31 | -29.9 | -25.1 | -10.6 | -7.99 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2,336 | -5,336 | -1,761 | -70.4 | -11.4 |